English
简体中文
Total: £ 56.28
Published Date: 2025-11-10 | Pages: 150 | Tables: 158 | Medical Care
The global Antibody Drug Conjugate CDMO market is projected to grow from US$ 3059 million in 2024 to US$ 7331 million by 2031, at a CAGR of 12.7% (2025-2031), driven by critical product segments and diverse end‑use applications.
Antibody-Drug Conjugate (ADC) is a type of targeted cancer therapy that utilizes monoclonal antibodies to deliver cytotoxic drugs directly to cancer cells, minimizing damage to healthy cells. ADCs have shown promising results in treating various types of cancers.A Contract Development and Manufacturing Organization (CDMO) specializes in providing services related to the development, manufacturing, and testing of pharmaceuticals, including biologics like ADCs.
Antibody Drug Conjugates (ADCs) represent one of the fastest-growing and most sophisticated segments in targeted cancer therapy. By combining the precise targeting ability of monoclonal antibodies with the potent cell-killing effect of cytotoxic drugs, ADCs offer a powerful treatment strategy that minimizes harm to healthy tissues.
However, ADCs are among the most complex biologic-drug hybrids to manufacture — they require expertise in biologics production, high-potency active pharmaceutical ingredient (HPAPI) synthesis, advanced conjugation technology, and high-containment fill-finish capabilities.
This is where Contract Development and Manufacturing Organizations (CDMOs) come in. They provide specialized technical infrastructure and know-how for biopharma companies that want to develop and commercialize ADCs without building expensive in-house capacity.
The ADC CDMO market has grown significantly in recent years, fueled by an expanding pipeline of ADCs in clinical trials and rising numbers of commercial approvals. Leading CDMOs now offer end-to-end solutions covering monoclonal antibody production, payload synthesis, conjugation, and sterile, high-containment packaging.
Growing Number of Approved ADCs and Robust Clinical Pipeline
More than a dozen ADCs have received regulatory approval worldwide, with blockbusters like Enhertu®, Padcev®, and Polivy® demonstrating strong commercial success. At the same time, hundreds of new ADCs are in preclinical and clinical development targeting a wide range of cancers and even some non-oncology indications. This expanding pipeline fuels sustained demand for expert CDMO services from early development through to commercial scale-up.
Rising Demand for End-to-End Solutions
Pharma companies increasingly prefer one-stop CDMO partners that can handle the entire ADC value chain — from cell line development to final fill-finish — under a single quality system and contract. This integrated model simplifies supply chains, shortens development timelines, and reduces risk, giving CDMOs with full-spectrum ADC capabilities a competitive edge.
Increased Investment in High-Potency Manufacturing Capacity
As the ADC market expands, leading CDMOs are investing heavily to expand or build new high-containment suites and HPAPI production lines. This growth is critical because HPAPI synthesis and handling require specialized equipment, isolated work areas, and rigorous operator safety systems.
Companies like Lonza, WuXi XDC, Piramal Pharma Solutions, and Sterling Pharma Solutions have made significant capital investments to meet the increasing global demand.
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Antibody Drug Conjugate CDMO market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Lonza Group
Porton Pharma Solutions
WuXi XDC
BOC Sciences
Asymchem
Catalent Biologics
3PBIOVIAN
Genscript
AGC Biologics
MabPlex
ChemExpress
Abzena
Ajinomoto Bio-Pharma Services
BSP Pharmaceuticals
AbbVie Contract Manufacturing
TOT Biopharm
Huadong Medicine
Innovent Biologics
Zhenhao Biology
Porton Pharma Solutions
Segment by Type
Cleavable Linker ADCs
Non-Cleavable Linker ADCs
Segment by Application
Small and Medium-sized Pharmaceutical Companies
Large Pharmaceutical Companies
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Antibody Drug Conjugate CDMO study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Antibody Drug Conjugate CDMO: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Antibody Drug Conjugate CDMO Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Cleavable Linker ADCs
1.2.3 Non-Cleavable Linker ADCs
1.3 Market Segmentation by Application
1.3.1 Global Antibody Drug Conjugate CDMO Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Small and Medium-sized Pharmaceutical Companies
1.3.3 Large Pharmaceutical Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Antibody Drug Conjugate CDMO Revenue Estimates and Forecasts 2020-2031
2.2 Global Antibody Drug Conjugate CDMO Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Antibody Drug Conjugate CDMO Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Antibody Drug Conjugate CDMO Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Cleavable Linker ADCs Market Size by Players
3.3.2 Non-Cleavable Linker ADCs Market Size by Players
3.4 Global Antibody Drug Conjugate CDMO Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Antibody Drug Conjugate CDMO Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Antibody Drug Conjugate CDMO Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Antibody Drug Conjugate CDMO Market Size by Type (2020-2031)
6.4 North America Antibody Drug Conjugate CDMO Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Antibody Drug Conjugate CDMO Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Antibody Drug Conjugate CDMO Market Size by Type (2020-2031)
7.4 Europe Antibody Drug Conjugate CDMO Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Antibody Drug Conjugate CDMO Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Type (2020-2031)
8.4 Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Antibody Drug Conjugate CDMO Market Size by Type (2020-2031)
9.4 Central and South America Antibody Drug Conjugate CDMO Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Antibody Drug Conjugate CDMO Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Antibody Drug Conjugate CDMO Market Size by Type (2020-2031)
10.4 Middle East and Africa Antibody Drug Conjugate CDMO Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Antibody Drug Conjugate CDMO Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Lonza Group
11.1.1 Lonza Group Corporation Information
11.1.2 Lonza Group Business Overview
11.1.3 Lonza Group Antibody Drug Conjugate CDMO Product Features and Attributes
11.1.4 Lonza Group Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.1.5 Lonza Group Antibody Drug Conjugate CDMO Revenue by Product in 2024
11.1.6 Lonza Group Antibody Drug Conjugate CDMO Revenue by Application in 2024
11.1.7 Lonza Group Antibody Drug Conjugate CDMO Revenue by Geographic Area in 2024
11.1.8 Lonza Group Antibody Drug Conjugate CDMO SWOT Analysis
11.1.9 Lonza Group Recent Developments
11.2 Porton Pharma Solutions
11.2.1 Porton Pharma Solutions Corporation Information
11.2.2 Porton Pharma Solutions Business Overview
11.2.3 Porton Pharma Solutions Antibody Drug Conjugate CDMO Product Features and Attributes
11.2.4 Porton Pharma Solutions Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.2.5 Porton Pharma Solutions Antibody Drug Conjugate CDMO Revenue by Product in 2024
11.2.6 Porton Pharma Solutions Antibody Drug Conjugate CDMO Revenue by Application in 2024
11.2.7 Porton Pharma Solutions Antibody Drug Conjugate CDMO Revenue by Geographic Area in 2024
11.2.8 Porton Pharma Solutions Antibody Drug Conjugate CDMO SWOT Analysis
11.2.9 Porton Pharma Solutions Recent Developments
11.3 WuXi XDC
11.3.1 WuXi XDC Corporation Information
11.3.2 WuXi XDC Business Overview
11.3.3 WuXi XDC Antibody Drug Conjugate CDMO Product Features and Attributes
11.3.4 WuXi XDC Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.3.5 WuXi XDC Antibody Drug Conjugate CDMO Revenue by Product in 2024
11.3.6 WuXi XDC Antibody Drug Conjugate CDMO Revenue by Application in 2024
11.3.7 WuXi XDC Antibody Drug Conjugate CDMO Revenue by Geographic Area in 2024
11.3.8 WuXi XDC Antibody Drug Conjugate CDMO SWOT Analysis
11.3.9 WuXi XDC Recent Developments
11.4 BOC Sciences
11.4.1 BOC Sciences Corporation Information
11.4.2 BOC Sciences Business Overview
11.4.3 BOC Sciences Antibody Drug Conjugate CDMO Product Features and Attributes
11.4.4 BOC Sciences Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.4.5 BOC Sciences Antibody Drug Conjugate CDMO Revenue by Product in 2024
11.4.6 BOC Sciences Antibody Drug Conjugate CDMO Revenue by Application in 2024
11.4.7 BOC Sciences Antibody Drug Conjugate CDMO Revenue by Geographic Area in 2024
11.4.8 BOC Sciences Antibody Drug Conjugate CDMO SWOT Analysis
11.4.9 BOC Sciences Recent Developments
11.5 Asymchem
11.5.1 Asymchem Corporation Information
11.5.2 Asymchem Business Overview
11.5.3 Asymchem Antibody Drug Conjugate CDMO Product Features and Attributes
11.5.4 Asymchem Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.5.5 Asymchem Antibody Drug Conjugate CDMO Revenue by Product in 2024
11.5.6 Asymchem Antibody Drug Conjugate CDMO Revenue by Application in 2024
11.5.7 Asymchem Antibody Drug Conjugate CDMO Revenue by Geographic Area in 2024
11.5.8 Asymchem Antibody Drug Conjugate CDMO SWOT Analysis
11.5.9 Asymchem Recent Developments
11.6 Catalent Biologics
11.6.1 Catalent Biologics Corporation Information
11.6.2 Catalent Biologics Business Overview
11.6.3 Catalent Biologics Antibody Drug Conjugate CDMO Product Features and Attributes
11.6.4 Catalent Biologics Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.6.5 Catalent Biologics Recent Developments
11.7 3PBIOVIAN
11.7.1 3PBIOVIAN Corporation Information
11.7.2 3PBIOVIAN Business Overview
11.7.3 3PBIOVIAN Antibody Drug Conjugate CDMO Product Features and Attributes
11.7.4 3PBIOVIAN Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.7.5 3PBIOVIAN Recent Developments
11.8 Genscript
11.8.1 Genscript Corporation Information
11.8.2 Genscript Business Overview
11.8.3 Genscript Antibody Drug Conjugate CDMO Product Features and Attributes
11.8.4 Genscript Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.8.5 Genscript Recent Developments
11.9 AGC Biologics
11.9.1 AGC Biologics Corporation Information
11.9.2 AGC Biologics Business Overview
11.9.3 AGC Biologics Antibody Drug Conjugate CDMO Product Features and Attributes
11.9.4 AGC Biologics Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.9.5 AGC Biologics Recent Developments
11.10 MabPlex
11.10.1 MabPlex Corporation Information
11.10.2 MabPlex Business Overview
11.10.3 MabPlex Antibody Drug Conjugate CDMO Product Features and Attributes
11.10.4 MabPlex Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 ChemExpress
11.11.1 ChemExpress Corporation Information
11.11.2 ChemExpress Business Overview
11.11.3 ChemExpress Antibody Drug Conjugate CDMO Product Features and Attributes
11.11.4 ChemExpress Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.11.5 ChemExpress Recent Developments
11.12 Abzena
11.12.1 Abzena Corporation Information
11.12.2 Abzena Business Overview
11.12.3 Abzena Antibody Drug Conjugate CDMO Product Features and Attributes
11.12.4 Abzena Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.12.5 Abzena Recent Developments
11.13 Ajinomoto Bio-Pharma Services
11.13.1 Ajinomoto Bio-Pharma Services Corporation Information
11.13.2 Ajinomoto Bio-Pharma Services Business Overview
11.13.3 Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Product Features and Attributes
11.13.4 Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.13.5 Ajinomoto Bio-Pharma Services Recent Developments
11.14 BSP Pharmaceuticals
11.14.1 BSP Pharmaceuticals Corporation Information
11.14.2 BSP Pharmaceuticals Business Overview
11.14.3 BSP Pharmaceuticals Antibody Drug Conjugate CDMO Product Features and Attributes
11.14.4 BSP Pharmaceuticals Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.14.5 BSP Pharmaceuticals Recent Developments
11.15 AbbVie Contract Manufacturing
11.15.1 AbbVie Contract Manufacturing Corporation Information
11.15.2 AbbVie Contract Manufacturing Business Overview
11.15.3 AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Product Features and Attributes
11.15.4 AbbVie Contract Manufacturing Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.15.5 AbbVie Contract Manufacturing Recent Developments
11.16 TOT Biopharm
11.16.1 TOT Biopharm Corporation Information
11.16.2 TOT Biopharm Business Overview
11.16.3 TOT Biopharm Antibody Drug Conjugate CDMO Product Features and Attributes
11.16.4 TOT Biopharm Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.16.5 TOT Biopharm Recent Developments
11.17 Huadong Medicine
11.17.1 Huadong Medicine Corporation Information
11.17.2 Huadong Medicine Business Overview
11.17.3 Huadong Medicine Antibody Drug Conjugate CDMO Product Features and Attributes
11.17.4 Huadong Medicine Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.17.5 Huadong Medicine Recent Developments
11.18 Innovent Biologics
11.18.1 Innovent Biologics Corporation Information
11.18.2 Innovent Biologics Business Overview
11.18.3 Innovent Biologics Antibody Drug Conjugate CDMO Product Features and Attributes
11.18.4 Innovent Biologics Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.18.5 Innovent Biologics Recent Developments
11.19 Zhenhao Biology
11.19.1 Zhenhao Biology Corporation Information
11.19.2 Zhenhao Biology Business Overview
11.19.3 Zhenhao Biology Antibody Drug Conjugate CDMO Product Features and Attributes
11.19.4 Zhenhao Biology Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.19.5 Zhenhao Biology Recent Developments
11.20 Porton Pharma Solutions
11.20.1 Porton Pharma Solutions Corporation Information
11.20.2 Porton Pharma Solutions Business Overview
11.20.3 Porton Pharma Solutions Antibody Drug Conjugate CDMO Product Features and Attributes
11.20.4 Porton Pharma Solutions Antibody Drug Conjugate CDMO Revenue and Gross Margin (2020-2025)
11.20.5 Porton Pharma Solutions Recent Developments
12 Antibody Drug Conjugate CDMOIndustry Chain Analysis
12.1 Antibody Drug Conjugate CDMO Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Antibody Drug Conjugate CDMO Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Antibody Drug Conjugate CDMO Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Antibody Drug Conjugate CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Antibody Drug Conjugate CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Antibody Drug Conjugate CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Antibody Drug Conjugate CDMO Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Antibody Drug Conjugate CDMO Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Antibody Drug Conjugate CDMO Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Antibody Drug Conjugate CDMO Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Antibody Drug Conjugate CDMO by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate CDMO as of 2024)
Table 11. Global Antibody Drug Conjugate CDMO Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Antibody Drug Conjugate CDMO Companies Headquarters
Table 13. Global Antibody Drug Conjugate CDMO Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Antibody Drug Conjugate CDMO Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Antibody Drug Conjugate CDMO Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Antibody Drug Conjugate CDMO Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Antibody Drug Conjugate CDMO Revenue by Application (2026-2031) & (US$ Million)
Table 21. Antibody Drug Conjugate CDMO High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Antibody Drug Conjugate CDMO Growth Accelerators and Market Barriers
Table 25. North America Antibody Drug Conjugate CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Antibody Drug Conjugate CDMO Growth Accelerators and Market Barriers
Table 27. Europe Antibody Drug Conjugate CDMO Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Antibody Drug Conjugate CDMO Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Antibody Drug Conjugate CDMO Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Antibody Drug Conjugate CDMO Investment Opportunities and Key Challenges
Table 31. Central and South America Antibody Drug Conjugate CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Antibody Drug Conjugate CDMO Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Antibody Drug Conjugate CDMO Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Lonza Group Corporation Information
Table 35. Lonza Group Description and Major Businesses
Table 36. Lonza Group Product Features and Attributes
Table 37. Lonza Group Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Lonza Group Revenue Proportion by Product in 2024
Table 39. Lonza Group Revenue Proportion by Application in 2024
Table 40. Lonza Group Revenue Proportion by Geographic Area in 2024
Table 41. Lonza Group Antibody Drug Conjugate CDMO SWOT Analysis
Table 42. Lonza Group Recent Developments
Table 43. Porton Pharma Solutions Corporation Information
Table 44. Porton Pharma Solutions Description and Major Businesses
Table 45. Porton Pharma Solutions Product Features and Attributes
Table 46. Porton Pharma Solutions Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Porton Pharma Solutions Revenue Proportion by Product in 2024
Table 48. Porton Pharma Solutions Revenue Proportion by Application in 2024
Table 49. Porton Pharma Solutions Revenue Proportion by Geographic Area in 2024
Table 50. Porton Pharma Solutions Antibody Drug Conjugate CDMO SWOT Analysis
Table 51. Porton Pharma Solutions Recent Developments
Table 52. WuXi XDC Corporation Information
Table 53. WuXi XDC Description and Major Businesses
Table 54. WuXi XDC Product Features and Attributes
Table 55. WuXi XDC Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. WuXi XDC Revenue Proportion by Product in 2024
Table 57. WuXi XDC Revenue Proportion by Application in 2024
Table 58. WuXi XDC Revenue Proportion by Geographic Area in 2024
Table 59. WuXi XDC Antibody Drug Conjugate CDMO SWOT Analysis
Table 60. WuXi XDC Recent Developments
Table 61. BOC Sciences Corporation Information
Table 62. BOC Sciences Description and Major Businesses
Table 63. BOC Sciences Product Features and Attributes
Table 64. BOC Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. BOC Sciences Revenue Proportion by Product in 2024
Table 66. BOC Sciences Revenue Proportion by Application in 2024
Table 67. BOC Sciences Revenue Proportion by Geographic Area in 2024
Table 68. BOC Sciences Antibody Drug Conjugate CDMO SWOT Analysis
Table 69. BOC Sciences Recent Developments
Table 70. Asymchem Corporation Information
Table 71. Asymchem Description and Major Businesses
Table 72. Asymchem Product Features and Attributes
Table 73. Asymchem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Asymchem Revenue Proportion by Product in 2024
Table 75. Asymchem Revenue Proportion by Application in 2024
Table 76. Asymchem Revenue Proportion by Geographic Area in 2024
Table 77. Asymchem Antibody Drug Conjugate CDMO SWOT Analysis
Table 78. Asymchem Recent Developments
Table 79. Catalent Biologics Corporation Information
Table 80. Catalent Biologics Description and Major Businesses
Table 81. Catalent Biologics Product Features and Attributes
Table 82. Catalent Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Catalent Biologics Recent Developments
Table 84. 3PBIOVIAN Corporation Information
Table 85. 3PBIOVIAN Description and Major Businesses
Table 86. 3PBIOVIAN Product Features and Attributes
Table 87. 3PBIOVIAN Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. 3PBIOVIAN Recent Developments
Table 89. Genscript Corporation Information
Table 90. Genscript Description and Major Businesses
Table 91. Genscript Product Features and Attributes
Table 92. Genscript Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Genscript Recent Developments
Table 94. AGC Biologics Corporation Information
Table 95. AGC Biologics Description and Major Businesses
Table 96. AGC Biologics Product Features and Attributes
Table 97. AGC Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. AGC Biologics Recent Developments
Table 99. MabPlex Corporation Information
Table 100. MabPlex Description and Major Businesses
Table 101. MabPlex Product Features and Attributes
Table 102. MabPlex Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. MabPlex Recent Developments
Table 104. ChemExpress Corporation Information
Table 105. ChemExpress Description and Major Businesses
Table 106. ChemExpress Product Features and Attributes
Table 107. ChemExpress Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. ChemExpress Recent Developments
Table 109. Abzena Corporation Information
Table 110. Abzena Description and Major Businesses
Table 111. Abzena Product Features and Attributes
Table 112. Abzena Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Abzena Recent Developments
Table 114. Ajinomoto Bio-Pharma Services Corporation Information
Table 115. Ajinomoto Bio-Pharma Services Description and Major Businesses
Table 116. Ajinomoto Bio-Pharma Services Product Features and Attributes
Table 117. Ajinomoto Bio-Pharma Services Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Ajinomoto Bio-Pharma Services Recent Developments
Table 119. BSP Pharmaceuticals Corporation Information
Table 120. BSP Pharmaceuticals Description and Major Businesses
Table 121. BSP Pharmaceuticals Product Features and Attributes
Table 122. BSP Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. BSP Pharmaceuticals Recent Developments
Table 124. AbbVie Contract Manufacturing Corporation Information
Table 125. AbbVie Contract Manufacturing Description and Major Businesses
Table 126. AbbVie Contract Manufacturing Product Features and Attributes
Table 127. AbbVie Contract Manufacturing Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. AbbVie Contract Manufacturing Recent Developments
Table 129. TOT Biopharm Corporation Information
Table 130. TOT Biopharm Description and Major Businesses
Table 131. TOT Biopharm Product Features and Attributes
Table 132. TOT Biopharm Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. TOT Biopharm Recent Developments
Table 134. Huadong Medicine Corporation Information
Table 135. Huadong Medicine Description and Major Businesses
Table 136. Huadong Medicine Product Features and Attributes
Table 137. Huadong Medicine Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Huadong Medicine Recent Developments
Table 139. Innovent Biologics Corporation Information
Table 140. Innovent Biologics Description and Major Businesses
Table 141. Innovent Biologics Product Features and Attributes
Table 142. Innovent Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Innovent Biologics Recent Developments
Table 144. Zhenhao Biology Corporation Information
Table 145. Zhenhao Biology Description and Major Businesses
Table 146. Zhenhao Biology Product Features and Attributes
Table 147. Zhenhao Biology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 148. Zhenhao Biology Recent Developments
Table 149. Porton Pharma Solutions Corporation Information
Table 150. Porton Pharma Solutions Description and Major Businesses
Table 151. Porton Pharma Solutions Product Features and Attributes
Table 152. Porton Pharma Solutions Revenue (US$ Million) and Gross Margin (2020-2025)
Table 153. Porton Pharma Solutions Recent Developments
Table 154. Raw Materials Key Suppliers
Table 155. Distributors List
Table 156. Market Trends and Market Evolution
Table 157. Market Drivers and Opportunities
Table 158. Market Challenges, Risks, and Restraints
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Antibody Drug Conjugate CDMO Product Picture
Figure 2. Global Antibody Drug Conjugate CDMO Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Cleavable Linker ADCs Product Picture
Figure 4. Non-Cleavable Linker ADCs Product Picture
Figure 5. Global Antibody Drug Conjugate CDMO Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Small and Medium-sized Pharmaceutical Companies
Figure 7. Large Pharmaceutical Companies
Figure 8. Antibody Drug Conjugate CDMO Report Years Considered
Figure 9. Global Antibody Drug Conjugate CDMO Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 10. Global Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 11. Global Antibody Drug Conjugate CDMO Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 12. Global Antibody Drug Conjugate CDMO Revenue Market Share by Region (2020-2031)
Figure 13. Global Antibody Drug Conjugate CDMO Revenue Market Share Ranking (2024)
Figure 14. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 15. Cleavable Linker ADCs Revenue Market Share by Player in 2024
Figure 16. Non-Cleavable Linker ADCs Revenue Market Share by Player in 2024
Figure 17. Global Antibody Drug Conjugate CDMO Revenue Market Share by Type (2020-2031)
Figure 18. Global Antibody Drug Conjugate CDMO Revenue Market Share by Application (2020-2031)
Figure 19. North America Antibody Drug Conjugate CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 20. North America Top 5 Players Antibody Drug Conjugate CDMO Revenue (US$ Million) in 2024
Figure 21. North America Antibody Drug Conjugate CDMO Revenue (US$ Million) by Type (2020 - 2031)
Figure 22. North America Antibody Drug Conjugate CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 23. US Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 24. Canada Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 25. Mexico Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 26. Europe Antibody Drug Conjugate CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 27. Europe Top 5 Players Antibody Drug Conjugate CDMO Revenue (US$ Million) in 2024
Figure 28. Europe Antibody Drug Conjugate CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 29. Europe Antibody Drug Conjugate CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 30. Germany Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 31. France Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 32. U.K. Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 33. Italy Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 34. Russia Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Antibody Drug Conjugate CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Top 8 Players Antibody Drug Conjugate CDMO Revenue (US$ Million) in 2024
Figure 37. Asia-Pacific Antibody Drug Conjugate CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 38. Asia-Pacific Antibody Drug Conjugate CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 39. Indonesia Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 40. Japan Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 41. South Korea Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 42. Australia Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 43. India Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 44. Indonesia Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 45. Vietnam Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 46. Malaysia Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 47. Philippines Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 48. Singapore Antibody Drug Conjugate CDMO Revenue (2020-2031) & (US$ Million)
Figure 49. Central and South America Antibody Drug Conjugate CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Central and South America Top 5 Players Antibody Drug Conjugate CDMO Revenue (US$ Million) in 2024
Figure 51. Central and South America Antibody Drug Conjugate CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 52. Central and South America Antibody Drug Conjugate CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 53. Brazil Antibody Drug Conjugate CDMO Revenue (2020-2025) & (US$ Million)
Figure 54. Argentina Antibody Drug Conjugate CDMO Revenue (2020-2025) & (US$ Million)
Figure 55. Middle East and Africa Antibody Drug Conjugate CDMO Revenue YoY (2020-2031) & (US$ Million)
Figure 56. Middle East and Africa Top 5 Players Antibody Drug Conjugate CDMO Revenue (US$ Million) in 2024
Figure 57. South America Antibody Drug Conjugate CDMO Revenue (US$ Million) by Type (2020-2031)
Figure 58. Middle East and Africa Antibody Drug Conjugate CDMO Revenue (US$ Million) by Application (2020-2031)
Figure 59. GCC Countries Antibody Drug Conjugate CDMO Revenue (2020-2025) & (US$ Million)
Figure 60. Israel Antibody Drug Conjugate CDMO Revenue (2020-2025) & (US$ Million)
Figure 61. Egypt Antibody Drug Conjugate CDMO Revenue (2020-2025) & (US$ Million)
Figure 62. South Africa Antibody Drug Conjugate CDMO Revenue (2020-2025) & (US$ Million)
Figure 63. Antibody Drug Conjugate CDMO Industry Chain Mapping
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
